sars-cov-2

Documents about sars-cov-2

• Severe Acute Respiratory Syndrome CoV 2 COVID-19 Survey and Vaccination Coverage in the Sickle Cell Population in Ile-De-France#812954ClinicalTrials.gov
• AI-guided multi-omics analysis identifies NPC1-modulated susceptibility to SARS-CoV-2 infection under PM(2.5) exposure.#221108NCBI PubMed Central
• Emerging SARS-CoV-2 variant BA.3.2 is more poorly neutralized by responses focused on other contemporary strains#374154Europe PMC
• SARS-CoV-2 seroprevalence in the adult detainees of the Paris area in 2021: A multicenter cross-sectional study#391813HAL (France)
• ADDRESSING THE CHALLENGES OF PRACTICAL APPLICATION IN UNDERGRADUATE EDUCATION PROGRAMS#14662DataCite
• ADDRESSING THE CHALLENGES OF PRACTICAL APPLICATION IN UNDERGRADUATE EDUCATION PROGRAMS#14663DataCite
• Dysregulated host miRNAs with antiviral potential against SARS-CoV-2 identified from COVID-19 patients.#125471NCBI PubMed Central
• Optical label-free detection of SARS-CoV-2: investigating platform spectroscopic properties for oligonucleotide targeting.#135950NCBI PubMed Central
• Paired wastewater and clinical genomics across metropolitan and hospital catchments reveals SARS-CoV-2 relevant mutations#154933bioRxiv / medRxiv
• Helminth infection is linked to an impaired neutralisation response to SARS-CoV-2 post vaccination#160120Europe PMC
• Maternal-infant immune signatures in infants at risk for SARS-CoV-2-associated neurodevelopmental disorders.#170503NCBI PubMed Central
• Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)#174974ClinicalTrials.gov
• SARS-CoV-2 membrane protein recruits PP2A to dephosphorylate the nucleocapsid and promote virion production.#193531NCBI PubMed Central
• Early Mucosal Type II, but not Type I, Interferon as a Key Regulator of SARS-CoV-2 Replication#226096CaltechDATA
• Modelling the interplay between responsive individual vaccination decisions and the spread of SARS-CoV-2.#242403NCBI PubMed Central
• A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection#283091ClinicalTrials.gov
• Neuroimaging markers of cognitive fatigue in individuals with post-acute sequelae of SARS-CoV-2 infection.#298745NCBI PubMed Central
• Interactomics of SARS-CoV-2 Macrodomain 1 Reveals Putative Clients of ADP-Ribosyl Hydrolase Activity.#317693NCBI PubMed Central
• RNA Folding Energy of Long-Range Genomic Interactions Regulates Discontinuous Transcription in SARS-CoV-2.#317854NCBI PubMed Central
• Targeting SARS-CoV-2 Structural and Accessory Proteins: Emerging Opportunities for Small-Molecule Coronavirus Antivirals.#317895NCBI PubMed Central
• The Direct Effects of SARS-COV-2 Spike Protein Subunit S1 on Secondary Hemostasis and Fibrinolysis#397910Aperta
• A PhaseⅡ Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine#414373ClinicalTrials.gov
• Before blaming SARS-CoV-2 infection or vaccination for acute peripheral artery occlusion, rule out differential causes#415039HAL (France)
• SARS-CoV-2 and diabetes: a post-pandemic reappraisal#416623Springer Nature OA
• Effects of genomic recombination on SARS-CoV-2 evolution and the growth of the recombinant variant XFG in Germany#419970bioRxiv / medRxiv
• Reductions in commuting mobility predict geographic differences in SARS-CoV-2 prevalence in New York City#468155Harvard DASH
• ЭФФЕКТИВНОСТЬ ЭКСТРЕННОЙ ПРОФИЛАКТИКИ ИНФЕКЦИИ SARS-CoV-2 ИММУНОСТИМУЛИРУЮЩИМ КОМПЛЕКСОМ АНТИГЕНОВ УСЛОВНО-ПАТОГЕННЫХ БАКТЕРИЙ#619391CyberLeninka
• Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults#651133ClinicalTrials.gov
• Antimicrobial peptides as computational candidates for SARS-CoV-2 papain-like protease inhibition.#662808NCBI PubMed Central
• SARS-CoV-2 ORF8: an accessory protein at the interface of immune evasion and inflammation.#678502NCBI PubMed Central
• A Study of Immune Responses to the Virus That Causes COVID-19#802134ClinicalTrials.gov
• To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M#803085ClinicalTrials.gov
• ANalyzing Olfactory Dysfunction Mechanisms In COVID-19#805170ClinicalTrials.gov
• Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III#830376ClinicalTrials.gov
• Use of the Mask and Current Pandemic#832047ClinicalTrials.gov
• A Trial of Remdesivir in Adults With Mild and Moderate COVID-19#842178ClinicalTrials.gov
• A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19#847382ClinicalTrials.gov
• Diagnostic and Prognostic Biomarkers in SARS-CoV-2 Infections#851997ClinicalTrials.gov
• Sotrovimab Expanded Access Treatment Protocol (COVID-19)#864973ClinicalTrials.gov
• Creating a Sustainable Infrastructure for SARS-CoV-2 Testing (COVID-19) at Syringe Exchange Programs#867417ClinicalTrials.gov
• Immunity to Infection in Healthy Participants and Participants With Cancer#871618ClinicalTrials.gov
• COVID-19 Among Healthcare Workers in Belgian Hospitals#881343ClinicalTrials.gov
• Association Between BMI and COVID-19#883168ClinicalTrials.gov
• Characteristics of Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)#803291ClinicalTrials.gov
• Observational Study of Intranasal IVIG in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patients Undergoing Medical Tourism#871230ClinicalTrials.gov
• A Study of TAK-019 in Healthy Japanese Adults (COVID-19)#353348ClinicalTrials.gov
• Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant Recipients#802128ClinicalTrials.gov
• Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.#876660ClinicalTrials.gov
• Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol#830961ClinicalTrials.gov
• Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia#860532ClinicalTrials.gov